Results 191 to 200 of about 3,105,692 (378)
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
Correction: Essential Role of the ESX-5 Secretion System in Outer Membrane Permeability of Pathogenic Mycobacteria. [PDF]
PLOS Genetics Staff
doaj +1 more source
Patient, parent and provider perspectives on sickle cell disease genetics research in Jamaica. [PDF]
Jones K, Stewart K, Asnani M, Royal CD.
europepmc +1 more source
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source
Abstracts of papers presented at the 21st Genetics Society's Mammalian Genetics and Development Workshop held at the Institute of Child Health, University College London on 11 November 2010 [PDF]
Nicholas D. E. Greene +2 more
openalex +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source

